Alzamend Neuro Inc (ALZN) Q4 2024 Earnings Report

Revenue and gross margin: QQ4 2024 revenue of $76,110 with gross profit of -$12,685, yielding a gross margin of -16.7%. Management reported ongoing R&D and G&A expenditures (R&D $183,430; G&A $666,635) leading to total operating expenses of $837,379 and an operating loss of $850,064. Net income for the quarter was -$851,529 and earnings per share (EPS) was -$1.24. YoY and QoQ revenue changes are not disclosed in a way that allows a clean year-over-year comparison for the exact quarter; the reported metrics indicate continued negative profitability characteristic of early-stage biotech.

Profitability and margins: The company posted negative EBITDA of -$837,380 and an EBITDAR ratio of approximately -11.00 (as reported). The net income margin stands at about -11.19%, and the operating income margin is -11.17%. The strong SG&A component relative to revenue is the primary driver of the operating loss. Although the stock is pre-revenue, the line items reflect the immaterial top-line that comes with a Phase II-stage biotech.

Cash flow and liquidity: Cash flow from operating activities was -$1,426,707 for QQ4 2024. Investing activities used $147,243 in PPE and other investments, while financing activities generated $1,519,888, producing a net cash increase of $93,181. The company ended the period with $376,048 in cash and cash equivalents and total debt of $300,714. Net debt stood at -$75,334, reflecting a cash position that is modest relative to the ongoing cash burn. Free cash flow was -$1,279,464, underscoring the funding gap that financing is attempting to fill on a quarterly basis.

Balance sheet and capitalization: Total assets were $631,588, with current assets at $455,242 and total current liabilities of $3,225,773. Liabilities exceed assets by a wide margin, and stockholders’ equity sits at approximately -$2,594,185. Deferred revenue is negative at -$2,925,059, which may reflect timing differences in grant or collaboration funding versus revenue recognition. The company carries a short-term debt burden of $300,714 and does not report long-term debt in the period, suggesting a liquidity profile that is dependent on ongoing financing to meet near-term obligations.

No QQ4 2024 earnings call transcript data is provided in the dataset. As a result, no management quotes or verbal guidance from the earnings call can be cited here. Investors should rely on the disclosed financial statements and the accompanying management discussion and analysis (MD&A) in the 10-Q/press releases for any qualitative commentary. When transcript data becomes available, a theme-based synthesis (strategy, operations, market conditions) with quotes and context will be provided.

ALZN represents a high-risk, high-reward opportunity typical of early-stage biotech names with a single late-stage or near-term pipeline catalyst. The near-term investment thesis is anchored in AL001 Phase II progress and the potential for strategic partnerships that could de-risk the business and improve liquidity. However, the immediate financial picture remains challenging: negative profitability, significant cash burn, limited cash on hand, and a balance sheet dominated by liabilities and negative equity. A favorable Phase II readout or a viable licensing deal could unlock substantial upside, potentially driving a re-rating of the stock. Absent clinical breakthroughs or a compelling monetization strategy, the company faces continued financing needs and dilution pressure. Investors should weigh the probability and timing of AL001 milestones against the likelihood and terms of future fundraising, while monitoring broader biotech funding sentiment and any partnership announcements.